ALSO NOTED: FDA OKs Iomai trial; Agency panel to review Factive; Curis opens China subsidiary; and much more...

> The FDA has approved a Phase I trial of Iomai's flu vaccine patch. The trial will enlist 300 volunteers to compare the effectiveness of delivering the vaccine to the cells in the skin compared to an injectable. Report

> Trading in shares of Oscient Pharmaceuticals was suspended in advance of an FDA panel meeting to consider expanding the use of Factive tablets to treat acute sinus infections. Regulatory staffers have questioned Factive's link to an allergic rash and some analysts say an approval is unlikely. Report

> Cambridge, MA-based Curis has opened a subsidiary in China to advance a cancer program utilizing the country's "cost-efficient medicinal chemistry industry." Release

> Canada's ConjuChem Biotechnologies produced positive Phase I/II data on its experimental therapy for type 2 diabetes. Release

> Antisoma says its drug AS1404 in combination with Erbitux reduces the growth of lung cancer xenografts. Report

> VioQuest Pharmaceuticals has dosed the first patient in its Phase I/IIa clinical trial of VQD-002, triciribine-phosphate for leukemia. Release

> OXiGENE is planning to focus its ophthalmology strategy on oral or other non-intravitreal forms of administrations of Combretastatin A4 Phosphate (CA4P) for age-related macular degeneration. Release

> San Diego-based Arena Pharmaceuticals has begun dosing patients in the first of three planned Phase III clinical trials evaluating its lead drug candidate, lorcaserin hydrochloride, for the treatment of obesity. Release

And Finally… To understand health in America, you have to divide the country into eight "Americas," each with its own set of demographics, according to a new study. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.